July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Phase III studies of brolucizumab versus aflibercept in nAMD: 48-week primary and key secondary outcomes from HAWK/HARRIER
Author Affiliations & Notes
  • Glenn J Jaffe
    Duke University Eye Center, Durham, North Carolina, United States
  • Adrian H C Koh
    Eye and Retina Surgeons, Camden Medical Centre, Singapore, Singapore
  • Yuichiro Ogura
    Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
  • Andreas Weichselberger
    Novartis Pharma AG, Basel, Switzerland
  • Frank G. Holz
    University of Bonn, Bonn, Germany
  • Pravin U Dugel
    Retinal Consultants Arizona, Phoenix, Arizona, United States
  • Footnotes
    Commercial Relationships   Glenn Jaffe, Heidelberg Engineering, Novartis, Neurotech, pSivida (C); Adrian H Koh, Alcon, Allergan, Bayer, Boeringher Ingelheim, Carl Zeiss Meditec, Heidelberg Engineering, Novartis Pharma AG, Santen, Topcon (C); Yuichiro Ogura, Bayer (R); Andreas Weichselberger, Novartis Pharma AG (E); Frank Holz, Acucela, Alcon, Allergan, Bayer HealthCare, Carl Zeiss Meditec, Genentech, Heidelberg Engineering, Novartis, Optos (F), Acucela, Bayer HealthCare, Boehringer Ingelheim, Genentech, Heidelberg Engineering, Merz, Novartis, Roche (C), Heidelberg Engineering (R); Pravin Dugel, Alimera, Aerpio, Annidis, ArctixDx, Digisight, Irenix, Ophthotech, Clearside Biomedical, PanOptica (I), Bausch + Lomb Surgical, Bausch + Lomb Pharma, Genentech, Alcon Surgical, Alcon Pharmaceutical, NeoVista, MacuSight, ArticDx, ORA, Novartis, Allergan, Santen, Inc. Thrombogenics, Ophthotech, Lux BioScience, DigiSight, Roche, TopCon, Acucela, Pentavision, ORA Stealth, Biotherapeutics, Annidis, Clearside Biomedical, Optovue, Pentavision, Neurotech, Lutronic, Alimera Sciences, DOSE Medical, Aerpio, Omeros, Shire, Human Genetics, Opthea, Graybug Vision, Irenix, ByeOnics, PanOptica, Chengdu Kanghong Biotechnology, SciFluor Life Sciences, Allegro Eye (C)
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1624. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Glenn J Jaffe, Adrian H C Koh, Yuichiro Ogura, Andreas Weichselberger, Frank G. Holz, Pravin U Dugel; Phase III studies of brolucizumab versus aflibercept in nAMD: 48-week primary and key secondary outcomes from HAWK/HARRIER. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1624.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Brolucizumab is a single-chain antibody fragment with potent anti-VEGF attributes. Its molecular structure enables concentrated molar dosing and may facilitate effective tissue penetration, which together may support a long-lasting effect. This study compared the efficacy and safety of brolucizumab versus aflibercept.

Methods : Patients were randomized 1:1:1 to brolucizumab 3mg (n=358), 6mg (n=360) or aflibercept 2mg (n=360) (HAWK), or 1:1 with either brolucizumab 6mg (n=370) or aflibercept 2mg (n=369) (HARRIER), given as intravitreal injections. One eye of each patient was designated as the study eye. After three loading doses, brolucizumab patients were treated every 12 weeks (q12w), with the possibility of adjusting to 8-week dosing (q8) during the first q12 interval and at each scheduled q12 treatment visit (fig.1); aflibercept patients were treated on a q8w interval, as per label. The primary endpoint was non-inferiority of brolucizumab to aflibercept in best corrected visual acuity (BCVA) change from baseline at Week 48 (4 letter margin). Key secondary endpoints were average change in BCVA from baseline over weeks 36-48, proportion of patients on q12 treatment interval at Week 48 and change in anatomical and safety parameters.

Results : For the brolucizumab 6mg arm, 57% and 52% of patients, in HAWK and HARRIER respectively, were maintained on a q12w interval up to Week 48. Mean change in BCVA from baseline to Week 48 for brolucizumab was non-inferior versus aflibercept in both studies (p<0.0001, both studies). At Week 48 in HAWK, mean change in BCVA (±SE) for brolucizumab 3mg, brolucizumab 6mg and aflibercept 2mg was 6.1 (0.69), 6.6 (0.71) and 6.8 (0.71) ETDRS letters, respectively. At Week 48 in HARRIER, mean change in BCVA (±SE) for brolucizumab 6mg and aflibercept 2mg was 6.9 (0.61) and 7.6 (0.61) letters, respectively. Average change in BCVA over weeks 36-48 was also non-inferior (p<0.0001, both studies). Reductions in central subfield thickness were greater, and significantly fewer patients had IRF and/or SRF in the brolucizumab 6mg group versus aflibercept. Overall, safety signals were comparable between treatment arms.

Conclusions : Brolucizumab met the primary endpoint of non-inferiority in BCVA change versus aflibercept, with the majority of brolucizumab patients maintained on a q12w dosing regimen after loading until Week 48.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


Fig 1: Treatment regimens

Fig 1: Treatment regimens


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.